abcam

ab251159

Anti-MIP-3 beta/CCL19 antibody [EPR7044(2)] - BSA and Azide free

Recombinant | RabMAb

Key facts

Isotype	IgG
Host species	Rabbit
Storage buffer	pH: 7.2 - 7.4 Constituents: PBS
Form	Liquid
Clonality	Monoclonal
Immunogen	The exact immunogen used to generate this antibody is proprietary information.
Carrier free	Yes
Clone number	EPR7044(2)
Purification technique	Affinity purification Protein A
Concentration	0.988 mg/mL The concentration of this product may be batch-dependent Batch concentration finder →

Reactivity data

WB

Tested

Species	Human
Dilution info	-

Notes	-

Flow Cyt (Intra)

Tested

Species	Human
Dilution info	-
Notes	-

Target data

See full target information CCL19

Function	May play a role not only in inflammatory and immunological responses but also in normal lymphocyte recirculation and homing. May play an important role in trafficking of T-cells in thymus, and T-cell and B-cell migration to secondary lymphoid organs. Binds to chemokine receptor CCR7. Recombinant CCL19 shows potent chemotactic activity for T-cells and B-cells but not for granulocytes and monocytes. Binds to atypical chemokine receptor ACKR4 and mediates the recruitment of beta-arrestin (ARRB1/2) to ACKR4.

Storage

Shipped at conditions	Blue Ice
Appropriate short-term storage conditions	+4°C
Appropriate long-term storage conditions	+4°C
Storage information	Do Not Freeze

Notes

ab251159 is the carrier-free version of ab192877.

Patented technology

Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?

This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.

Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.

Compatibility
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary	MIP-3 beta also known as CCL19 is a chemokine involved in immune responses. It weighs around 11 kDa and is encoded by the CCL19 gene. MIP-3 beta does its function by binding to its receptor CCR7 which is common in lymph nodes and other lymphoid tissues. It recruits and directs the migration of immune cells especially T cells and dendritic cells navigating them towards lymphoid tissues. This makes MIP-3 beta integral in initiating and modulating immune responses.
Biological function summary	MIP-3 beta helps direct cell trafficking within the lymphoid organs. It is not part of a complex but its interaction with the CCR7 receptor is essential for its biological activity. This binding plays a role in the development of secondary lymphoid organs and immune surveillance. Furthermore MIP-3 beta supports the homing of immune cells to appropriate locations impacting both innate and adaptive immune responses.
Pathways	MIP-3 beta is associated with the chemokine signaling pathway and the immune system pathway. Through these pathways it interacts with proteins like CCR7 and other chemokines that regulate leukocyte migration and activation. These pathways ensure local and systemic immune responses are efficiently orchestrated impacting inflammation and immune regulation.
Associated diseases and disorders	MIP-3 beta has connections to autoimmune diseases like rheumatoid arthritis and cancer. Its deregulation can result in abnormal immune surveillance contributing to the pathology of these conditions. MIP-3 beta regulates immune cell infiltration and any imbalance may also link it to other inflammatory disorders. Relations to proteins such as CCR7 in these conditions emphasize its role in disease pathogenesis and highlight its potential as a therapeutic target.

Product promise

Tested

We have tested this species and application combination and it works. It is covered by our product promise.

Expected

We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.

Predicted

This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.

Not recommended

We do not recommend this combination. It is not covered by our product promise.


We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

---


2 product images



Flow Cytometry (Intracellular) - Anti-MIP-3 beta/CCL19 antibody [EPR7044(2)] - BSA and Azide free (ab251159)

MIP-3 beta/CCL19 Flow Cytometry (Intracellular) staining using rabbit Anti-MIP-3 beta/CCL19 antibody

This data was developed using ab192877, the same antibody clone in a different buffer formulation.
Intracellular flow cytometric analysis of 2% paraformaldehyde-fixed A549 cells labeling MIP-3 beta/CCL19 with ab192877 at 1/170 dilution (red) compared with a rabbit monoclonal IgG isotype control (black) and an unlabelled control (cells without incubation with primary antibody and secondary antibody; blue). Goat anti rabbit IgG (FITC) at 1/150 dilution was used as the secondary antibody.



Western blot - Anti-MIP-3 beta/CCL19 antibody [EPR7044(2)] - BSA and Azide free (ab251159)

This data was developed using ab192877, the same antibody clone in a different buffer formulation.
Blocking and dilution buffer: 5% NFDM/TBST.

All lanes:
Western blot - Anti-MIP-3 beta/CCL19 antibody [EPR7044(2)] (ab192877) at 1/20000 dilution

All lanes:
Human MIP-3 beta/CCL19 recombinant protein (aa22-98) at 10 µg

Secondary

All lanes:
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugate at 1/1000 dilution

Predicted band size: 11 kDa

Observed band size: 11 kDa

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.